Pharmaceuticals Biotechnology and Life Sciences
More
-
Over the past couple of days, a couple of analyst reports have come into my inbox regarding the results of the so-called "CRYSTAL" study of ImClone's Erbitux on metastatic colorectal cancer. ImClone shares Erbitux with Bristol-Myers Squibb. The drug is approved for colon and head and neck cancers, but they're testing it on other tumor types. CRYSTAL is an acronym, but you won't believe how they stretched to create it: Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer. Which came first? The acronym or the study description? Anyway, I digress. Crazy clinical trial acronyms are for another day, another blog entry.
-
Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.
-
M&A news and quarterly updates provided some of the catalysts behind the most actively traded stocks on Monday.
-
A new study says if a drug is quickly developed that delays the onset of Alzheimer's Disease it would save the U.S. economy trillions of dollars.
-
When it comes to the medical space, proprietary products are where you want to be, Cramer says. Kinetic Concepts' strength in this area make it a good pick for Speculation Friday here on Mad Money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Regulation approval in China recently hurt this company, but Cramer says there's reason to believe the business is on the MEND.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
The slump in retail is actually a good thing for investors, Cramer says. Plus, a sleeper stock worth watching and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Several investment banks slashed their ratings on Amgen shares following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and Johnson & Johnson.
-
M&A news and analyst actions were some of the catalysts behind the most actively traded stocks on Friday.
-
The founder and former CEO of ImClone Systems, Sam Waksal, who is now sitting in prison for his role in the trading scandal that ensnared Martha Stewart, had a reputation for rubbing elbows with the New York glitterati and the Hollywood set. Well, it looks like ImClone is reliving its past.
-
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
-
Analyst actions and earnings updates were some of the catalysts behind the most actively traded stocks on Thursday.
-
While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.
-
Analyst upgrades and earnings reports were some of the catalysts behind the most actively traded stocks on Wednesday.
-
Bristol-Myers Squibb and Isis Pharmaceuticals on Wednesday announced a deal -- worth up to $192 million -- in which Bristol-Myers will license Isis' early-stage cholesterol drug. Why is the pharmaceutical giant paying such a high price for something as yet untested on humans? Isis Chairman and CEO Stanley Crooke explained the deal to CNBC's Mike Huckman, on "Morning Call."
-
Back from Boston and BIO (Biotechnology Industry Organization) 2007. Organizers claim they've got record attendance of more than 20,000 people. That'd be nearly three times the number of people who went when it was last held in Boston at the height of the human genome/biotech bubble in 2000.BIO is also boasting the appearance of the queen, although not the one who was at the White House last night. Queen Noor of Jordan delivers the keynote address today. BIO lost one of its other keynoters yesterday. Massachusetts' own Senator Kennedy was supposed to speak ahead of Michael J. Fox at lunch on Monday, but instead he sent a videotaped message.
-
Household products, oil drillers, healthcare, materials, telecom, international brokers, agriculture, aerospace, biotech – these are the sectors Cramer thinks will rally the hardest. He suggests you buy now.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
M&A news and earnings updates provided some of the catalysts for Monday's most actively traded stocks.
-
Earnings blowouts from Google and strong guidance from two key names in the industrial sector were among the catalysts for Friday's most-active stocks.
-
There are few stocks that could run up 20 points in a hurry that Cramer wouldn’t recommend getting out of, but Nastech is one of them. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.